Literature DB >> 7607055

Clinical heterogeneity of insulin dependent diabetes mellitus in Korea.

K U Lee1, S W Kim, J Y Park, K S Ko, B D Rhee, H K Min.   

Abstract

This study was undertaken to find out how many current Korean patients with insulin dependent diabetes mellitus (IDDM) had a previous history of non-insulin requiring phase. Fasting serum C-peptide levels were measured in the 2300 diabetic patients during the visit to the Asan Medical Center, Seoul, Korea. Fifty-nine patients showed fasting serum C-peptide levels below 0.13 nmol/l. These 59 patients were classified further into two groups according to their history of insulin requirement: group A who required insulin within 1 year after diagnosis or presented initially as diabetic ketoacidosis and group B who had non-insulin requiring phase at least for 1 year (median: 5 years; range: 1-23 years). Twenty-six patients (44%) were classified into group A and 27 patients (46%) into group B. Median age of onset was 26 years (range: 10-50 years) and 45 years (range: 23-73 years) in groups A and B, respectively (P < 0.001). While the two groups had similar values in the current and maximum body mass indices, sex ratio and the prevalence of islet cell antibodies, 58% of the group A and 7% of the group B patients had histories of diabetic ketoacidosis. These results suggest a clinical heterogeneity in patients with IDDM in Korea.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607055     DOI: 10.1016/0168-8227(95)01027-b

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  1 in total

1.  Prevalence and clinical characteristics of fulminant type 1 diabetes mellitus in Korean adults: A multi-institutional joint research.

Authors:  Sun Ok Song; Jae-Seung Yun; Seung-Hyun Ko; Yu-Bae Ahn; Bo-Yeon Kim; Chul-Hee Kim; Ja Young Jeon; Dae Jung Kim; Da Hae Seo; So Hun Kim; Jung Hyun Noh; Da Young Lee; Kyung-Soo Kim; Soo-Kyung Kim
Journal:  J Diabetes Investig       Date:  2021-08-31       Impact factor: 4.232

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.